Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Single-Blind, Multicenter, Phase III, Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.

NCT05110898 is registered in ClinicalTrials.gov with Brainfarma Industria Química e Farmacêutica S/A as lead sponsor.

NCT NCT05110898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05110898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Single-Blind, Multicenter, Phase III, Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.
Lead sponsor
Brainfarma Industria Química e Farmacêutica S/A
Phase
Phase 3
Overall status
Unknown status
Start date
August 1, 2022
Completion date
October 1, 2023
Enrollment
400 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, hypertension,essential